Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 9/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1587729 | 0.92 | AR (0.41) | CETPARCRHR1CNR2LTC4S | |
| SCHEMBL1587641 | 0.91 | CETP (0.40) | CETPARCRHR1CNR2LTC4S | |
| SCHEMBL12775280 | 0.84 | AR (0.42) | CETPARCRHR1CNR2LTC4S | |
| SCHEMBL1588409 | 0.84 | CETP (0.46) | CETPARLTC4S | |
| SCHEMBL1587674 | 0.84 | CETP (0.40) | CETPARCRHR1CNR2 | |
| SCHEMBL1588361 | 0.83 | AR (0.41) | CETPARCRHR1CNR2LTC4S | |
| SCHEMBL4500073 | 0.83 | AR (0.36) | CETPARCRHR1CNR2 | |
| SCHEMBL4496659 | 0.83 | CRHR1 (0.40) | CETPARCRHR1 | |
| SCHEMBL1587587 | 0.83 | CETP (0.37) | CETPCRHR1 | |
| SCHEMBL2081889 | 0.83 | CETP (0.38) | CETPLTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | CETP 1/4885AR 2196/4885CRHR1 3679/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885AR 2196/4885CRHR1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.